百济神州 ONC
$406.96 +$19.71 (+5.09%)
休市 · Nov 6, 8:20 pm ET · 最新盘后价 $408.80 +0.45%
开盘$399.00
昨收$387.25
当日区间$399.00 – $410.71
成交量941.7K
市值$46.49B
市盈率（TTM）51.8
股息率–
ONC 相关新闻
匹配 BeiGene 或代码 ONC 的头条新闻，按最新排序。
- UBS Group: Most Chinese biotech firms exceeded sales expectations in the first half; global R&D catalysts will be key in the second half. Top pick: BeiGene (ONC.US) 正面
- Day 3 of the 2026 National Reimbursement Drug List (NRDL) negotiations: Intensive talks on new "-tinib" drugs as star companies such as BeiGene and Kelun Biotech take the stage.
- CLSA: Fundamentals of China's biotechnology sector remain solid; top picks are BeiGene (06160), Innovent Bio (01801), and WeLiShengBo (09887).
- UBS Group: Chinese biotech firms’ H1 sales largely exceeded expectations; global R&D catalysts in H2 will be key; BeiGene is the top pick. 正面
- The Capital Group increased its holdings in BeiGene (06160.HK) by 1.9494 million H shares, valued at approximately USD 699 million.
- Barclays Maintains BeiGene(ONC.US) With Buy Rating, Raises Target Price to $415 正面
- BeiGene (688235): Strong sales of its flagship product and continued expansion of its pipeline. 正面
- Record of Investor Relations Activities of BeiGene, Ltd. (August 2026) 正面
- BeiGene (688235): Strong U.S. Market Performance and Efficient Advancement of Solid Tumor R&D 正面
- A Quick Look at Today's Ratings for BeiGene(ONC.US), With a Forecast Between $400 to $466
- BeiGene, Ltd. Investor Relations Activity Log – 20260806
- BeiGene: U.S. Stock Market Announcement: Quarterly Report on Form 10-Q
- BeiGene (688235): Profit growth to remain robust in Q2 2026; full-year revenue and profit guidance raised. 正面
- BeiGene: Special Report on the Deposit and Actual Use of Funds Raised in the First Half of 2026 by BeiGene, Ltd. 正面
- RBC Capital Maintains BeiGene(ONC.US) With Buy Rating, Maintains Target Price $450
暂无评论——快来第一个聊聊 ONC。
登录后参与讨论。